For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
The Sunday Read: ‘What I Saw Working at The National Enquirer During Donald Trump’s Rise’
How One Family Lost $900,000 in a Timeshare Scam
The Staggering Success of Trump’s Trial Delay Tactics
Trump's Abortion Dilemma
How Tesla Planted the Seeds for Its Own Potential Downfall
The Eclipse Chaser
The Sunday Read: ‘What Deathbed Visions Teach Us About Living’
An Engineering Experiment to Cool the Earth
Israel’s Deadly Airstrike on the World Central Kitchen
The Accidental Tax Cutter in Chief
Kids Are Missing School at an Alarming Rate
Ronna McDaniel, TV News and the Trump Problem
From Serial: Season 4 - Guantánamo
Hamas Took Her, and Still Has Her Husband
The Newest Tech Start-Up Billionaire? Donald Trump
Democrats’ Plan to Save the Republican House Speaker
The United States vs. the iPhone
A Terrorist Attack in Russia
The Sunday Read: ‘My Goldendoodle Spent a Week at Some Luxury Dog ‘Hotels.’ I Tagged Along.’
Chuck Schumer on His Campaign to Oust Israel’s Leader
Create your
podcast in
minutes
It is Free
Up First
Post Reports
The Journal.
The Ezra Klein Show
Today, Explained